



**Supplementary Materials for Financial Statements
For the Interim Period Ended September 30, 2007**

November 13, 2007

Yakult Honsha Co., Ltd.
Public Relations Department
IR Section

URL <http://ir.yakult.co.jp/>

Contents

Consolidated

1. Major Increases (Decreases) in Consolidated Balance Sheet	1	Page
2. Major Increases (Decreases) in Consolidated Statements of Income	2	
3. Performance Overview	3	
4. Segment Information	4-7	
5. Overview of Overseas Companies	8-9	

Non-Consolidated

1. Major Increases (Decreases) in Non-consolidated Balance Sheet	10	
2. Major Increases (Decreases) in Non-consolidated Statements of Income	11	
3. Performance Overview	12	
4. Breakdown of Sales	13-14	
5. Head Office Employees	15	
6. Yakult Sales Company	15	
7. Sales Personnel by Department	15	
8. Average figure of Yakult Lady	15	

Reference

1. Expansion of Indication and New Drug Development Pipeline	16	
2. Situation of Yakult Group	17	
3. Sales amount breakdown of the third quarter overseas companies (Preliminary figure)	18	

About a numeric display of this material

1. Unit of money : Less than one million yen is rounded down.
2. Quantity results: Less than 1000 is rounded off.
3. Year on year percentage: The second place is rounded off after the decimal point.

Consolidated

1. Major Increases (Decreases) in Consolidated Balance Sheet

(Millions of yen)

	As of Mar. 31 2007	As of Sep.30 2007	Increase (Decrease)	Primary reason for change
Total Assets	354,539	382,189	27,649	
Current assets				
Cash and deposits	77,109	83,787	6,678	Increase in overseas subsidiaries
Notes and accounts receivable	48,426	56,783	8,356	Increase in parent company
Inventories	30,548	31,579	1,030	
Deferred tax assets	4,254	5,799	1,544	
Others	5,241	9,212	3,970	
Fixed assets				
Tangible fixed assets				
Buildings and structures	34,513	37,151	2,637	Increase in plants in Japan
Land	32,889	33,687	797	
Others	34,186	38,212	4,025	Increase of machinery, vehicles and construction-in-progress
Intangible fixed assets	5,101	4,867	(233)	
Investments and other assets				
Investment securities	70,053	68,275	(1,777)	Decrease in parent company
Deferred tax assets	4,347	5,091	743	
Others	7,865	7,740	(124)	
Total Liabilities	93,334	107,574	14,240	
Current liabilities				
Notes and accounts payable	26,183	29,765	3,581	Increase in parent company
Short-term bank loans	9,026	14,834	5,807	Increase in parent company
Allowance for bonuses	3,875	4,751	876	
Others	28,688	30,629	1,940	
Fixed liabilities				
Liability for retirement benefits	16,457	16,500	43	
Others	9,102	11,092	1,989	Increase of long-term borrowings
Total Net Assets	261,205	274,614	13,409	

Note) Minority interests are included in Total Net Assets.

2. Major Increases (Decreases) in Consolidated Statements of Income

(Millions of yen)

	Previous interim period (2006.4~9)	Current interim period (2007.4~9)	Increase (Decrease)		Primary reason for change	Forecasts※ (2007.4~9)
			Amount	%		
Net sales	136,079	146,386	10,307	7.6	Increase in parent company and overseas subsidiaries	144,000
(Sales by business segments)						
Food and beverages	116,325	122,875	6,549	5.6	Increase in overseas subsidiaries	
Pharmaceuticals	12,695	16,700	4,004	31.5	Increase of "Elplat"	
Others	7,058	6,811	(246)	(3.5)		
Cost of sales	62,082	65,235	3,152	5.1		
Gross profit	73,997	81,151	7,154	9.7		
Gross profit margin (%)	54.4	55.4				
Selling, general and administrative expenses	62,057	68,610	6,553	10.6		
Selling expenses	29,218	31,967	2,748	9.4	Increase in overseas subsidiaries	
General and administrative expenses	32,838	36,643	3,805	11.6	Increase in parent company	
Operating income	11,939	12,540	600	5.0		11,000
Operating income margin (%)	8.8	8.60				
(Operating income by business segments)						
Food and beverages	13,049	12,705	(343)	(2.6)		
Pharmaceuticals	4,439	5,776	1,336	30.1	Increase of "Elplat"	
Others	302	334	32	10.6		
Corporate expenses	(5,851)	(6,275)	(424)	7.3		
Non-operating income	6,688	6,660	(28)	(0.4)		
Foreign exchange gain	800	262	(537)			
Royalty income	1,414	1,570	156		Increase in Pharmaceuticals	
Investment gains from the equity method	2,238	2,023	(215)			
Others	2,235	2,803	568			
Non-operating expenses	643	932	288	44.8		
Loss on disposal of merchandise and finished goods	315	173	(142)			
Others	327	759	431			
Ordinary income	17,984	18,268	283	1.6		16,200
Ratio of ordinary income to Net sales (%)	13.2	12.5				
Extraordinary gains	374	2,109	1,735	463.4	Increase in parent company (settlement income)	
Extraordinary losses	1,526	778	(748)	(49.0)		
Income before income taxes and minority interests	16,832	19,599	2,766	16.4		
Income taxes	6,002	7,484	1,482			
Income taxes-deferred	543	(457)	(1,000)			
Minority interests	1,949	2,263	313			
Net income	8,338	10,309	1,971	23.6		9,000
Ratio of net income to Net sales (%)	6.1	7.0				

Note) Revised forecast of first half of FY2008, announced on July 27, 2007

3. Performance Overview

(1) Breakdown of Statements of Income

(Millions of yen %)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Net sales	136,079	104.6	273,099	102.0	146,386	107.6	313,000	114.6
Operating income	11,939	125.9	23,893	109.8	12,540	105.0	21,800	91.2
Ordinary income	17,984	122.8	33,607	105.7	18,268	101.6	31,000	92.2
Net income	8,338	142.5	14,805	102.5	10,309	123.6	15,500	104.7

(2) Ratios of Consolidated to Non-consolidated Results

(Times)

	Fiscal year ended March 31, 2007		Fiscal year ending March 31, 2008	
	Result of 1st half	Result of Full fiscal year	Result of 1st half	Forecast of Full fiscal year
Net sales	1.62	1.69	1.67	1.86
Operating income	4.49	4.03	4.12	6.61
Ordinary income	2.87	2.28	2.50	2.58
Net income	2.30	1.79	1.76	1.78

(3) Breakdown of Equity Method

(Millions of yen %)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Breakdown of Equity Method	2,238	108.0	3,447	100.2	2,023	90.4	3,500	101.5

(4) Major Items in selling, general and administrative expenses

(Millions of yen %)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Advertising expenses	7,211	100.2	13,384	99.3	8,772	121.6	—	—
Sales promotion expenses	3,121	101.4	6,605	88.2	3,269	104.7	—	—
Freight	4,581	106.0	9,079	107.0	4,829	105.4	—	—
Employee's salaries Provision for bonuses	14,295	103.6	26,077	107.3	15,729	110.0	—	—
Depreciation	1,757	118.1	3,590	116.9	2,012	114.5	—	—
Research and Development cost	3,336	92.4	6,721	96.8	5,034	150.9	—	—

(5) Capital investment, Depreciation expense

(Millions of yen %)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Capital investment	7,033	133.3	16,786	144.1	9,365	133.2	33,000	196.6
Depreciation expense	4,338	108.4	9,025	107.4	※1 5,213	120.2	※2 11,300	125.2

※1: 167 million yen of prior year's depreciation under revised regulation of depreciation is included.

※2: 334 million yen of prior year's depreciation under revised regulation of depreciation is included.

Breakdown of investment

	Fiscal year ended March 31, 2007		Fiscal year ending March 31, 2008	
	Investment in Parent company	Investment in Plants(subsidiaries)	Investment in Parent company	Investment in Plants(subsidiaries)
Capital investment	9.3 billion yen	2.1 billion yen	14.9 billion yen	6.0 billion yen
		3.2 billion yen	10.4 billion yen	

4. Segment Information

(1) Information about Business Segments

① Result of 1st half Fiscal year ended March 31, 2007

(Millions of yen %)

	Food and beverages	Pharmaceuticals	Others	Total	※ Eliminations/ corporate	Consolidated
Net sales	116,325	12,695	7,058	136,079	---	136,079
Percentage of net sales	85.5	9.3	5.2	100.0	---	100.0
Year on year	102.4	126.4	109.7	104.6	---	104.6
Operating expenses	103,276	8,256	6,755	118,288	5,851	124,139
Year on year	102.7	103.9	109.8	103.1	98.6	102.9
Operating income (loss)	13,049	4,439	302	17,791	(5,851)	11,939
Year on year	100.0	211.9	108.2	115.4	98.6	125.9
Operating income margin	11.2	35.0	4.3	---	---	8.8

② Result of 1st half Fiscal year ended March 31, 2008

	Food and beverages	Pharmaceuticals	Others	Total	※ Eliminations/ corporate	Consolidated
Net sales	122,875	16,700	6,811	146,386	---	146,386
Percentage of net sales	83.9	11.4	4.7	100.0	---	100.0
Year on year	105.6	131.5	96.5	107.6	---	107.6
Operating expenses	110,170	10,924	6,476	127,570	6,275	133,846
Year on year	106.7	132.3	95.9	107.8	107.3	107.8
Operating income (loss)	12,705	5,776	334	18,816	(6,275)	12,540
Year on year	97.4	130.1	110.6	105.8	107.3	105.0
Operating income margin	10.3	34.6	4.9	---	---	8.6

※Eliminations/ corporate・・・Mainly administrative expenses in parent company

③ Result of Full Fiscal year ended March 31, 2007

(Millions of yen %)

	Food and beverages	Pharmaceuticals	Others	Total	※ Eliminations/ corporate	Consolidated
Net sales	233,138	25,698	14,262	273,099	---	273,099
Percentage of net sales	85.4	9.4	5.2	100.0	---	100.0
Year on year	101.5	106.0	103.5	102.0	---	102.0
Operating expenses	207,033	16,283	14,039	237,356	11,849	249,206
Year on year	101.4	97.4	106.0	101.3	100.9	101.3
Operating income (loss)	26,105	9,414	223	35,743	(11,849)	23,893
Year on year	102.6	125.1	41.7	106.7	100.9	109.8
Operating income margin	11.2	36.6	1.6	---	---	8.7

④ Forecast of Full Fiscal year ending March 31, 2008

	Food and beverages	Pharmaceuticals	Others	Total	※ Eliminations/ corporate	Consolidated
Net sales	266,500	30,500	16,000	313,000	---	313,000
Percentage of net sales	85.1	9.8	5.1	100.0	---	100.0
Year on year	114.3	118.7	112.2	114.6	---	114.6
Operating expenses	242,700	20,600	15,900	279,200	12,000	291,200
Year on year	117.2	126.5	113.3	117.6	101.3	116.9
Operating income (loss)	23,800	9,900	100	33,800	(12,000)	21,800
Year on year	91.2	105.2	44.8	94.6	101.3	91.2
Operating income margin	8.9	32.5	0.6	---	---	7.0

※Eliminations/ corporate・・・Mainly administrative expenses in parent company

(2) Information about Geographical Segments

① Result of 1st half Fiscal year ended March 31, 2007

(Millions of yen %)

	Japan	Overseas Total	The Americas	Asia and Oceania	Europe	※ Eliminations/ corporate	Consolidated
Net sales	108,482	29,758	16,508	6,834	6,415	(2,161)	136,079
Percentage of net sales	79.7	21.9	12.1	5.0	4.7	(1.6)	100.0
Year on year	102.0	116.3	119.4	119.6	106.3	116.0	104.6
Operating expenses	98,915	21,534	11,065	5,815	4,653	3,689	124,139
Year on year	101.4	113.2	109.9	127.8	105.7	90.6	102.9
Operating income (loss)	9,566	8,224	5,442	1,019	1,762	(5,851)	11,939
Year on year	108.0	125.4	144.7	87.6	107.9	98.6	125.9
Operating income margin	8.8	27.6	33.0	14.9	27.5	---	8.8

② Result of 1st half Fiscal year ended March 31, 2008

	Japan	Overseas Total	The Americas	Asia and Oceania	Europe	※ Eliminations/ corporate	Consolidated
Net sales	114,122	36,995	20,503	8,450	8,042	(4,731)	146,386
Percentage of net sales	77.9	25.3	14.0	5.8	5.5	(3.2)	100.0
Year on year	105.2	124.3	124.2	123.6	125.4	218.9	107.6
Operating expenses	104,317	27,984	13,785	6,852	7,347	1,543	133,846
Year on year	105.5	130.0	124.6	117.8	157.9	41.8	107.8
Operating income (loss)	9,804	9,011	6,718	1,597	695	(6,275)	12,540
Year on year	102.5	109.6	123.4	156.7	39.5	107.3	105.0
Operating income margin	8.6	24.4	32.8	18.9	8.6	---	8.6

※Eliminations/ corporate・・・Elimination of inter-segment sales and mainly administrative expenses in parent company

③ Result of Full Fiscal year ended March 31, 2007

(Millions of yen %)

	Japan	Overseas Total	The Americas	Asia and Oceania	Europe	※ Eliminations/ corporate	Consolidated
Net sales	215,047	62,297	34,428	14,766	13,102	(4,245)	273,099
Percentage of net sales	78.8	22.8	12.6	5.4	4.8	(1.6)	100.0
Year on year	99.6	111.1	112.0	112.4	107.6	97.8	102.0
Operating expenses	195,205	46,396	23,178	12,339	10,878	7,604	249,206
Year on year	99.5	109.5	104.9	116.8	111.8	102.7	101.3
Operating income (loss)	19,842	15,900	11,250	2,426	2,223	(11,849)	23,893
Year on year	100.1	116.3	130.1	94.4	90.8	100.9	109.8
Operating income margin	9.2	25.5	32.7	16.4	17.0	---	8.7

④ Forecast of Full Fiscal year ending March 31, 2008

	Japan	Overseas Total	The Americas	Asia and Oceania	Europe	※ Eliminations/ corporate	Consolidated
Net sales	244,800	76,000	41,600	18,500	15,900	(7,800)	313,000
Percentage of net sales	78.2	24.3	13.3	5.9	5.1	(2.5)	100.0
Year on year	113.8	122.0	120.8	125.3	121.4	183.7	114.6
Operating expenses	227,100	59,900	29,100	15,600	15,200	4,200	291,200
Year on year	116.3	129.1	125.6	126.4	139.7	55.2	116.9
Operating income (loss)	17,700	16,100	12,500	2,900	700	(12,000)	21,800
Year on year	89.2	101.3	111.1	119.5	31.5	101.3	91.2
Operating income margin	7.2	21.2	30.0	15.7	4.4	---	7.0

※Eliminations/ corporate・・・Elimination of inter-segment sales and mainly administrative expenses in parent company

5. Overview of overseas companies

(1) Dairy Products sales(Bottles sold per day)

[Performance from January to June 2007]

(Jun 30 2007)

	Sales quantity (Thousands of bottles/day)	Year on year (%)	Started Business	Ratio of shareholding (%)	Consolidation Classification	Currency Unit	※1 Exchange rate		
							Average Jan. ~ Sep.	Average Jan. ~ Jun.	Average Jan. ~ Jun.
							2007	2007	2006
Taiwan	1,170	89.4	Mar 1964	25.00	Equity method	TWD	3.623	3.659	3.581
Hong Kong	451	107.1	Jun 1969	80.00	Consolidated	HKD	15.28	15.42	14.89
Thailand	1,888	103.3	Jun 1971	---	---	THB	---	---	---
Korea	4,796	96.5	Aug 1971	38.30	Equity method	KRW	0.1281	0.1291	0.1209
Philippines	1,024	108.5	Oct 1978	40.00	Equity method	PHP	2.55	2.55	2.24
Singapore	156	114.4	Jul 1979	100.00	Consolidated	SGD	78.42	78.90	72.07
Indonesia	988	93.5	Jan 1991	100.00	Consolidated	IDR	0.0131	0.0134	0.0127
Australia	157	100.4	Feb 1994	100.00	Consolidated	AUD	98.29	97.68	85.85
Malaysia	92	141.9	Feb 2004	100.00	Consolidated	MYR	34.52	34.88	31.36
Guangzhou	372	138.9	Jun 2002	95.00	Consolidated	CNY	15.58	15.63	14.36
Shanghai	124	131.4	May 2005	100.00	Consolidated	CNY	15.58	15.63	14.36
Beijing	37	5403.8	Jun 2006	100.00	Consolidated	CNY	15.58	15.63	14.36
Shanghai Marketing	10	-	Apr 2007	100.00	Consolidated	CNY	15.58	15.63	14.36
China total	543	149.6							
Asia and Oceania total	11,263	100.2	Marketing Population: 468,086 thousand people Population ratio 2.41%						
Brazil	1,241	105.5	Oct 1968	51.36	Consolidated	BRL	60.24	59.48	53.37
Mexico	2,962	115.7	Oct 1981	61.21	Consolidated	MXN	10.89	11.01	10.62
Argentina	42	112.5	May 1997	100.00	Consolidated	ARS	38.60	39.19	37.85
USA	35	107.2	Oct 1999	100.00	Consolidated	USD	119.26	120.49	115.57
The Americas total	4,279	112.4	Marketing Population: 156,997 thousand people Population ratio 2.73%						
Netherlands	345	122.3	Apr 1994	100.00	Consolidated	EUR	160.96	160.61	142.71
Belgium	97	113.4	Apr 1995	100.00	Consolidated	EUR	160.96	160.61	142.71
United Kingdom	254	103.6	Apr 1996	100.00	Consolidated	GBP	237.60	238.16	207.29
Germany	162	91.4	Apr 1996	100.00	Consolidated	EUR	160.96	160.61	142.71
Austria	22	290.4	Dec 2005	100.00	Consolidated	EUR	160.96	160.61	142.71
Italy	8	-	Feb 2007	100.00	Consolidated	EUR	160.96	160.61	142.71
Europe total	888	111.4	Marketing Population: 238,176 thousand people Population ratio 0.37%						
Total	16,430	103.7	Marketing Population: 863,259 thousand people Population ratio 1.90%						

※1 Exchange Rate : Average Jan ~ Sep 2007 : used for Forecasts for the Fiscal year ending Mar 2008
Average Jan ~ Jun 2007 : used for the 1st half result of the Fiscal year ending Mar 2008
Average Jan ~ Jun 2006 : used for the 1st half result of the Fiscal year ended Mar 2007

(2)Yakult Ladies by Area and Percentage of Sales by Channel (* Except for Japan)

(%)

	Number of Yakult Ladies	Percentage of Sales by Channel (Volume)	
		Yakult Ladies	Stores
Asia and Oceania	21,925	71.7	28.3
The Americas	13,511	55.1	44.9
Europe	—	—	100.0
Total	35,436	63.5	36.5

As of the end of June 2007

(3)Other countries sold

Countries Sold	Company in charge
Luxembourg	Yakult Belgium
France	Yakult Europe
Spain	
Uruguay	Yakult Brazil
Brunei	Yakult Singapore
New Zealand	Yakult Australia
Ireland	Yakult UK
Canada	Yakult USA

(4)Plan for the future

- Sales operation of new countries (3 countries)
 - Italy(Feb 2007), Canada(Jul 2007),Vietnam(Sep 2007)
- Test Sales(in 2 countries)
 - France, Spain
- Currently undergoing feasibility studies
 - Indochina, Middleeast, and otherAsian countries(conducting local feasibility studies based on the assumption of market entry)
 - Europe, especially EU countries, and parts of Eastern Europe(conducting local feasibility studies based on the assumption of market entry)
 - Various countries in Latin America (conducting local feasibility studies based on the assumption of market entry)
- Operation of new plant
 - India (scheduled to operate on Dec,2007)
 - Vietnam (scheduled to operate on Apr,2008)

(5)Others

- HACCP Accreditation:Thailand,Korea, Singapore, Indonesia, Malaysia, Guangzhou, Brazil, Mexico, Europe.
- ISO14001 Accreditation:Guangzhou, Europe, United Kingdom.
- ISO9001 Accreditation:Hong Kong, Korea, Singapore, Indonesia, Australia, Guangzhou, Europe, United Kingdom.
- GMP Accreditation:Taiwan, Thailand, Guangzhou, Brazil, Mexico.

※HACCP, ISO14001, ISO9001, GMP・・・Refer to page17

Non-Consolidated

1. Major Increases (Decreases) in Nonconsolidated Balance Sheet

(Millions of yen)

	As of Mar. 31 2007	As of Sep. 30 2007	Increase (Decrease)	Primary reason for change
Total Assets	230,990	241,095	10,104	
Current assets				
Cash and deposits	12,159	10,923	(1,236)	Acquisition of fixed assets
Accounts receivable	41,324	48,434	7,110	Increase of sales due to seasonal factors
Inventories	23,986	24,553	567	
Others	7,842	9,582	1,740	
Fixed assets				
Tangible fixed assets				
Machinery and equipment	9,551	9,714	163	
Land	17,248	17,343	95	
Others	21,720	21,691	(29)	
Intangible fixed assets	3,253	3,123	(129)	
Investments and other assets				
Investment securities	39,173	35,813	(3,359)	Unrealized holding loss of investment securities
Investments in and advances to unconsolidated subsidiaries and associated companies	42,440	45,906	3,466	Additional investment to overseas subsidiaries and new establishment
Deferred tax assets	9,879	11,578	1,699	
Others	2,411	2,428	16	
Total Liabilities	65,824	74,713	8,888	
Current liabilities				
Notes and accounts payable	21,459	25,403	3,943	
Short-term bank loans	5,004	11,004	6,000	Commitment line for financing
Income taxes payable	3,047	4,189	1,141	
Allowance for bonuses	3,112	3,721	609	
Others	18,398	16,183	(2,215)	Decrease of accrued expenses
Fixed liabilities				
Liability for retirement benefits	12,130	12,104	(26)	
Others	2,671	2,106	(564)	
Total Net Assets	165,166	166,382	1,216	

2. Major Increases (Decreases) in Nonconsolidated Statements of Income

(Millions of yen)

	Previous interim period (2006.4~9)	Current interim period (2007.4~9)	Increase (Decrease)		Primary reason for change	Forecasts※ (2007.4~9)
			Amount	%		
Net sales	83,876	87,660	3,783	4.5		87,000
(Breakdown)						
Dairy products	38,414	37,921	(493)	(1.3)	Decrease of "Thorpedo", "Bansoreicha" and "Kurozu Drink"	
Juices and other beverages	24,849	22,643	(2,205)	(8.9)		
Cosmetics	3,506	3,399	(107)	(3.1)	Increase of "Elplat" and "Campto"	
Pharmaceuticals	12,695	16,700	4,004	31.5		
Others	4,410	6,995	2,585	58.6		
Cost of sales	50,159	52,349	2,190	4.4		
Gross profit	33,717	35,310	1,593	4.7		
Gross profit margin (%)	40.2	40.3	0.1			
Selling, general and administrative expenses	31,060	32,268	1,208	3.9		
Advertising expenses	6,218	4,774	(1,444)	(23.2)	Decrease of advertisement for "Thorpedo"	
Sales promotion expenses	2,135	2,079	(56)	(2.7)		
Others	22,705	25,415	2,710	11.9	Increase of research and development cost (Satraplatin)	
Operating income	2,657	3,041	384	14.5		3,000
Operating income margin (%)	3.2	3.5	0.3			
Non-operating income	3,888	4,671	783	20.1		
Dividend income	799	1,316	517			
Royalties in pharmaceuticals	1,358	1,505	146			
Others	1,729	1,848	119			
Non-operating expenses	282	409	127	45.3		
Ordinary income	6,263	7,303	1,040	16.6		6,300
Ratio of ordinary income to net sales (%)	7.5	8.3	0.9			
Extraordinary gains	178	2,008	1,830	1,027.2	Settlement of litigation of "Princeton Note"	
Settlement income	-	1,961	1,961			
Others	178	46	(131)			
Extraordinary losses	294	318	24	8.2		
Loss on sales and disposal of fixed assets	284	81	(203)			
Others	9	237	227			
Income before income taxes	6,146	8,993	2,846	46.3		
Income taxes	2,517	3,126	609	24.2		
Net income	3,629	5,866	2,237	61.6		4,900
Ratio of net income to net sales (%)	4.3	6.7	2.4			

※(Note) Revised forecast of first half of FY2008, announced on July 27, 2007

3. Performance Overview

(1) Breakdown of Statements of Income

(Millions of yen %)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Net sales	83,876	102.3	161,656	99.5	87,660	104.5	168,000	103.9
Operating income	2,657	117.6	5,925	117.4	3,041	114.5	3,300	55.7
Ordinary income	6,263	101.7	14,736	100.7	7,303	116.6	12,000	81.4
Net income	3,629	165.3	8,250	111.5	5,866	161.6	8,700	105.4

(2) Sales by Product Category

(Millions of yen %)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Dairy products	38,414	96.1	75,839	97.5	37,921	98.7	76,000	100.2
Juices and other beverages	24,849	102.1	44,490	100.5	22,643	91.1	42,000	94.4
Subtotal	63,263	98.4	120,330	98.6	60,564	95.7	118,000	98.1
Cosmetics	3,506	102.7	6,644	101.5	3,399	96.9	7,000	105.4
Pharmaceuticals	12,695	126.4	25,698	106.0	16,700	131.5	30,500	118.7
Others	4,410	104.7	8,982	93.6	6,995	158.6	12,500	139.2
Total	83,876	102.3	161,656	99.5	87,660	104.5	168,000	103.9

(3) Cost to Net sales Ratio

(%)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Increase (Decrease)	Result of Full fiscal year	Increase (Decrease)	Result of 1st half	Increase (Decrease)	Forecast of Full fiscal year	Increase (Decrease)
Cost to Net sales ratio	59.80	(0.85)	59.66	(0.07)	59.72	(0.08)	60.14	0.48

(4) Capital investments, Depreciation and amortization, Research and development costs

(Millions of yen %)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Capital investments	3,517	178.4	9,384	194.6	3,627	103.1	14,992	159.8
Depreciation and amortization	2,316	112.0	4,832	109.2	※1 2,749	118.7	※2 6,218	128.7
Research and development costs	3,347	92.4	6,744	96.8	5,054	151.0	9,771	144.9

※1: 166 million yen of prior year's depreciation under revised regulation of depreciation is included.

※2: 330 million yen of prior year's depreciation under revised regulation of depreciation is included.

Breakdown of investment

	Fiscal year ended March 31, 2007	Fiscal year ending March 31, 2008
Capital investments	Investment in domestic plants : 5.7 billion yen (for plants reorganization : 3.2 billion yen) Central institute : 2.7 billion yen	Investment in domestic plants : 9.3 billion yen (for plants reorganization : 2.7 billion yen) Central institute : 3.3 billion yen
Research and development costs	Pharmaceuticals : 2.5 billion yen Others : 4.2 billion yen	Pharmaceuticals : 4.7 billion yen Others : 5.0 billion yen

4. Breakdown of Sales

(1) Dairy Products sales (Bottles sold per day)

(Thousands of bottles/day %)

		Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
		Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Dairy Products	<i>Yakult</i>	3,071	94.3	3,035	98.8	3,255	106.0	3,131	103.2
	<i>Yakult LT</i>	109	81.6	95	76.3	79	72.1	66	69.4
	<i>Yakult 200</i>	68	65.1	34	36.8	---	---	---	---
	<i>Yakult 80Ace</i>	428	80.7	403	81.8	326	76.2	300	74.4
	<i>Yakult 80AceLT</i>	141	88.3	141	93.4	140	99.4	138	98.1
	<i>Yakult 300V</i>	174	73.4	155	74.9	137	79.0	137	88.7
	<i>Yakult 300VLT</i>	8	---	41	---	68	854.1	71	173.6
	<i>Yakult 400</i>	1,903	102.3	1,924	105.6	2,184	114.8	2,190	113.8
	Total for Yakult products	5,902	94.0	5,827	97.7	6,188	104.8	6,033	103.5
	<i>Bifia</i> ※1	---	---	5	---	60	---	54	1,129.0
	<i>Pretio</i>	241	65.9	306	94.6	309	128.1	312	102.0
	<i>Joie</i>	754	93.7	726	93.7	708	93.9	690	95.1
	<i>Bifiene</i> products ※2	671	---	625	165.6	485	72.3	480	76.8
	<i>Sofuhl</i> products ※3	613	102.8	594	102.7	557	90.9	563	94.7
	<i>Purela</i> products	224	84.1	217	86.7	202	90.0	206	95.0
	Fresh milk yogurt products ※4	---	---	---	---	20	---	31	---
Total for fermented milk	2,262	101.2	2,162	95.1	1,952	86.3	1,970	91.1	
Total	8,405	94.6	8,300	97.0	8,259	101.5	8,393	101.1	

※1 *Bifia* (sale on March 20, 2007)

※2 *Bifiene V* (sale discontinuance on March 19, 2007)

※3 *SofuhlLCS100* of the sale on March 24, 2006 is included.

※4 *Yakult full of fresh milk yogurt* :80g(new sale on June 4, 2007), 350g(new sale on October 1, 2007)

(2) Juices and Other Beverages sales (Total Bottles sold)

(Thousands of bottles/day %)

		Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
		Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
Juices and Other Beverages	<i>Bansoreicha</i>	31,845	99.2	56,183	95.0	26,821	84.2	56,235	100.1
	<i>Toughman</i>	39,244	91.8	67,659	91.9	38,535	98.2	68,709	101.6
	<i>Kurozu Drink</i>	44,851	93.7	77,823	94.4	34,981	78.0	67,967	87.3
	Soy milk drinks	27,052	79.9	48,834	77.7	20,627	76.2	37,500	76.8
	<i>Lemorea</i>	16,359	65.1	26,123	69.5	15,528	94.9	23,530	90.1
	<i>Thorpedo</i>	31,118	---	37,967	---	19,022	61.1	22,211	58.5
	<i>Juices</i>	40,402	85.1	71,758	87.7	39,638	98.1	67,500	94.1
	<i>Kininaruyasai</i>	44,327	114.5	80,802	113.5	44,021	99.3	81,000	100.2
	<i>Coffee Time</i>	36,297	117.2	67,283	111.9	30,377	83.7	60,000	89.2
	<i>FIRE</i>	36,625	91.0	82,622	93.5	38,257	104.5	88,700	107.4
	Coffee products total	72,921	102.4	149,904	101.0	68,633	94.1	148,700	99.2
	<i>Gogono-kocha</i>	15,437	102.4	33,843	107.4	16,269	105.4	34,343	101.5

(3) Percentage of Sales by Channel (April 1, 2007 to September 30, 2007) (%)

	Dairy products(Volume)		Juices and other beverages(Money)			
	Percentage of sales	Year on year	Percentage of sales		Year on year	
Yakult Ladies	60.5	98.8	43.5		91.3	
Stores, Vending machines, and Others	39.5	105.8	56.5	Vending machines	75.3	93.1
				Stores and Others	24.7	

Note: Actual sales statistics

① Breakdown of sales at Stores, Vending machines, and Others (Dairy products, Juices and other beverages)

	For first half ended Sep. 30, 2006		For fiscal year ended Mar. 31, 2007		For first half ended Sep. 30, 2007	
	Percentage of sales	Year on year	Percentage of sales	Year on year	Percentage of sales	Year on year
Supermarkets	33.5	98.8	35.9	106.4	34.2	102.9
Convenience stores	3.9	87.3	3.6	90.3	3.6	93.8
Offices (Vending machines)	20.0	98.5	19.3	100.9	19.8	99.3
Medical centers	10.8	96.8	10.9	97.2	10.5	97.9

② The number of vending machine

As of Mar. 31, 2007	As of Sep. 30, 2007	As of Mar. 31, 2008 (Forecast)
70,600	70,500	71,000

(4) Pharmaceuticals sales

(Millions of yen %)

	Fiscal year ended March 31, 2007				Fiscal year ending March 31, 2008			
	Result of 1st half	Year on year	Result of Full fiscal year	Year on year	Result of 1st half	Year on year	Forecast of Full fiscal year	Year on year
<i>Campto</i> (Japan)	2,065	114.8	4,611	126.7	2,417	117.0	4,330	93.9
<i>Campto</i> (Overseas)	2,380	53.6	3,611	35.8	3,531	148.4	4,470	123.8
North America	---	---	---	---	722	---	720	---
Europe	2,156	49.3	3,259	32.7	2,617	121.4	3,400	104.3
Other	224	350.0	352	275.0	192	85.7	350	99.4
<i>Campto</i> total	4,445	71.3	8,222	59.8	5,949	133.8	8,800	107.0
<i>Elplat</i>	7,640	247.2	16,231	178.1	10,009	131.0	20,200	124.4
Other pharmaceuticals	608	85.6	1,243	89.3	741	121.8	1,500	120.6
Total	12,695	126.4	25,698	106.0	16,700	131.5	30,500	118.7

Royalty income

(Millions of yen %)

Total	1,358	89.6	2,576	81.3	1,505	110.8	2,500	97.0

5. Head Office Employees

	Mar 31, 2007	Sep 30, 2007
Number of full-time employees	2,463	2,448
Medical Representatives	165	162

Note: Neither 377 proceeding person nor 67 non-regular employees are included in the number of above-mentioned employees.

6. Yakult Sales Company

(Sep 30, 2007)

Number of Yakult sales company	133	Consolidated subsidiaries	Affiliate applied to equity method	Comments
		23	0	Yakult Tokai Holdings Co., Ltd is not included

7. Sales Personnel by Department

	Mar 31, 2007	Sep 30, 2007
① Yakult Ladies	43,600	43,000
② Yakult Beauty Advisors	8,750	8,200

8. Average figure of Yakult Lady

		Sep 30, 2007
Merchandise they have / day	Dairy products	110 bottles
	Juice and others	20 bottles
Number of customers /1 Yakult lady	Individual	100
	Office	8
	Others	4
Age and Experience	Age	42 years old
	Experience	8 years
Activities	Working time	4.5 hours / day
	Working days	20 days / month

Reference

1. Expansion of Indications and New Drug Development Pipeline

(1) Expansion of *Campto* indications

(As of Sep. 2007)

	Indications	Stage	Date of application	Remarks
North America, South America, Oceania (Pfizer)	①Gastric cancer	Phase III completed	Under preparation of sNDA	Combination with 5FU/FA, first-line*1
	②Lung cancer (small cell lung cancer)	Phase III on-going	Undecided	Utilization of JCOG data*2
	③Pediatric cancer	Data exclusivity up to February 2008 has been given in the USA		
	④Breast cancer (Oral formulation)	Phase I on-going	Undecided	
Europe (Pfizer)	①Gastric cancer	Phase III completed	Under sNDA	Due to the transfer of <i>Campto</i> business to Pfizer, sNDA will be submitted in accordance with the progress of line extension studies.
	②Colorectal cancer (Adjuvant *3)	Phase III on-going	Undecided	
	③Lung cancer (Small cell Lung cancer)	Phase III on-going		

Note) *1 FA:Folic acid
*2 Japan Clinical Oncology Group
*3 Adjuvant:Post operation chemotherapy aiming for prevention of recurrence

(2) Expansion of *Elplat* indications

Under investigation of possibility for line extension with the following cancer

Colorectal cancer(Adjuvant)	Gastric cancer	Lung cancer (Non-small cell lung cancer)	Pancreatic cancer
-----------------------------	----------------	---	-------------------

(3) New drug development pipeline

Product	Indications	Licensor	Co-development partner	Stage	Remarks
① <i>Elplat</i> (Oxaliplatin) Development Code: L-OHP	Colorectal cancer	Debiopharm	(Independent development)	Approved in March 2005, and Launched in April 2005	Combination study with oral 5FU derivative are on-going
② <i>Irinotecan liposome</i> Development Code: IHL-305	Solid tumors	In-house	Terumo Corporation	Phase I	
③ <i>Soblidotin</i> Development Code: YHI-501	Solid tumors	ASKA Pharmaceutical Co.,	(Independent development)	Preparation of Phase II	
④ Satraplatin Development Code: YHI-601	Hormone-refractory prostate cancer	GPC Biotech	(Independent development)	Preparation of Phase I/ II	
⑤ Development Code: YHO- 13351	---	In-house	(Independent development)	Non-Critical Stage	BCRP Inhibitor

(4) National Health Insurance reimbursement price revision information (*Campto* injections and *Elplat* for injection)

	Since April, 2006 (yen)	As of the end on March, 2006 (yen)	Revision rate (%) (Decrease)	Reference (yen)
<i>Campto</i> injection (40mg/Vial)	8,520	8,928	(4.6)	FOLFIRI: About 190,000 yen/month*4
<i>Campto</i> injection (100mg/Vial)	19,022	20,050	(5.1)	
<i>Elplat</i> for injection 100mg	72,768	74,087	(1.8)	FOLFOX4: About 390,000 yen/month*4

*4 Monthly treatment cost including 5-FU and calcium leuvelofolinate is calculated on an assumption that body surface area is 1.6 Square meter.

(5) Patent expiration and data exclusivity

	Japan	North America	Europe
Patent expiration of <i>Campto</i> indications	Sep. 2007	Aug. 2007	Jul. 2009
Re-examination period for <i>Elplat</i> (Data exclusivity)	Mar. 2013 *5	---	---

*5 Extended from 6 to 8 years after approval

2.Situation of Yakult Group

<Yakult Honsha Plants >

(As of Sep. 2007)

	HACCP	ISO 9001	ISO 14001	The first stage of capital investment plan※1
Fukushima Plant	○		○	Under planning of new production building (start in 2nd half of FY 2008)
Ibaraki Plant	○		○	Complete new production building (start in March 2008)
Fuji Susono Plant	○	○	○	
Shizuoka Plant	○		○	
Kyoto Plant	○		○	
Fukuyama Plant	○		○	
Saga Plant	○		○	
Kumamoto Plant	○		○	
Total budget of capital investments				11.2 billion yen
Shonan Cosmetics Plant			○	
Fuji Susono Pharmaceuticals Plant			○	

<Subsidiary Plants >

	HACCP	ISO 9001	ISO 14001	The first stage of capital investment plan※1
Yakult Iwate Plant Co.,Ltd.	○		○	Complete new plant (start in March 2007) ※2
Yakult Chiba Plant Co.,Ltd.	○		○	
Yakult Aichi Plant Co.,Ltd.	○		○	Under improvement of new production building (complete in Mar 2008)
Yakult Osaka Plant Co.,Ltd.	○		○	
Yakult Kobe Plant Co.,Ltd.	○		○	
Yakult Fukuoka Plant Co.,Ltd.	○		○	Addition of production line (start in August 2006).
Total budget of capital investments				7.9 billion yen

※1: We will invest over 30 billion yen for the plants in the first stage (FY 2005-2008) and the second stage (FY2009-2012) of capital investment plan. The number of plants will change 11 from 19 at end of the capital investment plan.
(Total budget of the first stage: 19.1 billion yen)

※2: Yakult Iwate Plant Co.,Ltd. moved from Morioka City to Kitagami city (South Kitagami industrial estates) and newly was established.

<Yakult Central Institute and others >

	HACCP	ISO 9001	ISO 14001	Plan for capital investment
Yakult Central Institute			○ ※3	Main building (Food research facilities with fifth floors) rebuilding etc. Start of construction: March, 2006 Completion of construction : Schedule in March, 2010
Total budget of capital investments				7.8 billion yen

※3: The ISO14001 is acquired by the Chemical Analysis Center.
Note)

Yakult Food Industry Co.,Ltd. Yakult Chuo Logistics Co.,Ltd. Yakult Food Industry Co.,Ltd. Nihon Chlorella Co.,Ltd. acquired the ISO 14001.

HACCP :Hazard Analysis and Critical Control Point

International Organization for Standardization (ISO)

ISO 9001-- The International Standard for Quality Management Systems

ISO 14001-- The International Standard for Environmental Management Systems

Good Manufacturing Practice(GMP)

3.Sales amount breakdown of the third quarter overseas companies (Preliminary figure)

[Performance from January to September 2007]

	From January to September, 2007. (Preliminary figure)		Main Products	Base of production	Number of factories
	Sales quantity (Thousands of bottles/day)	Year on year (%)			
Taiwan	1,101	75.9	<i>Yakult, Joie</i>	○	1
Hong Kong	494	113.3	<i>Yakult</i>	○	1
Thailand	1,894	101.4	<i>Yakult</i>	○	1
Korea	4,762	94.6	<i>Yakult, Yakult Ace, Yakult400</i>	○	4
Philippines	1,016	107.2	<i>Yakult</i>	○	1
Singapore	157	113.1	<i>Yakult, Yakult Ace Light</i>	○	1
Indonesia	1,006	97.0	<i>Yakult, Yakult Ace ※5</i>	○	1
Australia	163	102.7	<i>Yakult, Yakult Light</i>	○	1
Malaysia	99	144.5	<i>Yakult Ace</i>	○	1
Vietnam ※1	0	---	<i>Yakult</i>	Indonesia	---
Guangzhou	428	144.7	<i>Yakult</i>	○	1
Shanghai ※2	144	137.0	<i>Yakult</i>	○	1
Beijing	46	660.6	<i>Yakult</i>	Shanghai	---
Shanghai Marketing ※3	21	---	<i>Yakult</i>	Shanghai	---
China total	640	156.8	---	---	---
Asia and Oceania total	11,333	98.1			
Brazil	1,238	105.0	<i>Yakult ,Yakult 400, Soful</i>	○	2
Mexico	2,960	114.4	<i>Yakult, Soful,Soful Drink type ※6</i>	○	2
Argentina	41	107.9	<i>Yakult</i>	Brazil	---
USA	38	115.3	<i>Yakult</i>	Mexico	---
The Americas total	4,277	111.5			
Netherlands	325	119.8	<i>Yakult, Yakult Light, Bifiene</i>	Yakult Europe	---
Belgium	94	114.3	<i>Yakult, Yakult Light, Bifiene</i>	Yakult Europe	---
United Kingdom	243	99.3	<i>Yakult, Yakult Light</i>	Yakult Europe	---
Germany	149	88.9	<i>Yakult, Yakult Light</i>	Yakult Europe	---
Austria	21	209.1	<i>Yakult</i>	Yakult Europe	---
Italy ※4	12	---	<i>Yakult</i>	Yakult Europe	---
Europe total	844	108.7			
Total	16,455	101.8			

※1: Yakult Vietnam began to sell the imported "Yakult" from Yakult Indonesia on Sep 2007.

※2: Sales Area of Shanghai : Shanghai city, Nanjing city

※3: Sales area of Shanghai Marketing : Tianjin city(Apr 2007), Suzhou city(Jun 2007), Wuxi city(Jun 2007), Hangzhou city(Sep 2007)

※4: Yakult Italy began to operate on Feb 2007.

※5: Yakult Indonesia began to sell the imported "Yakult Ace" from Yakult Malaysia on Sep 2007.

※6: Yakult Mexico began to sell the "Soful Drink type" on Sep 2007.

CAUTIONARY STATEMENT

Statements contained in these materials with respect to Yakult's plans, forecasts and other statements that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ substantially from expectations.

The information contained in these materials is not intended as a solicitation for investment. Furthermore, Yakult does not guarantee the accuracy of the contents of these materials. Yakult and the provider of these materials disclaim any responsibility for any loss or damage that should arise from the use of this information.